HER2-Targeted Therapy in UTUC: Results from the Phase II WUTSUP-02 Trial

In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Assoc. Prof. Yige Bao about his ESMO26 presentation of the Phase II WUTSUP-02 trial results. The WUTSUP-02 trial (ChiCTR2300067836) is a prospective, multi-centre, phase II study evaluating perioperative tislelizumab plus disitamab vedotin for upper tract urothelial carcinoma (UTUC).  They discuss the study design, patient population, and key trial endpoints, before reviewing the efficacy, survival, and safety results, including treatment-related adverse events. Their conversation also examines the clinical significance of these findings, their potential impact on the treatment landscape for UTUC, and the next steps needed to further evaluate HER2-targeted therapies and move toward broader clinical implementation. For more details on this study, you can read the abstract (https://bladder.uroonco.uroweb.org/pu...) on the UROONCO BCa Educational Platform. This interview was recorded at ESMO26. For more updates on bladder cancer, please visit our educational platform UROONCO BCa (https://bladder.uroonco.uroweb.org/) . For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts (https://podcasts.apple.com/us/podcast...) , Spotify (https://open.spotify.com/show/5wWPgGE...) , EAU YouTube channel (   / @uroweb  ) .